PL377555A1 - Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci - Google Patents
Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaciInfo
- Publication number
- PL377555A1 PL377555A1 PL377555A PL37755503A PL377555A1 PL 377555 A1 PL377555 A1 PL 377555A1 PL 377555 A PL377555 A PL 377555A PL 37755503 A PL37755503 A PL 37755503A PL 377555 A1 PL377555 A1 PL 377555A1
- Authority
- PL
- Poland
- Prior art keywords
- processes
- novel
- forms
- calcium
- preparing
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42532502P | 2002-11-12 | 2002-11-12 | |
| US10/370,897 US7501450B2 (en) | 2000-11-30 | 2003-02-19 | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL377555A1 true PL377555A1 (pl) | 2006-02-06 |
Family
ID=32314422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL377555A PL377555A1 (pl) | 2002-11-12 | 2003-11-12 | Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7501450B2 (pl) |
| EP (1) | EP1465865A2 (pl) |
| AU (1) | AU2003295529A1 (pl) |
| CA (1) | CA2505968C (pl) |
| LV (1) | LV13214B (pl) |
| PL (1) | PL377555A1 (pl) |
| WO (1) | WO2004043918A2 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1711489B1 (en) * | 2003-12-29 | 2012-12-26 | LEK Pharmaceuticals d.d. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| JP2007505944A (ja) * | 2004-07-22 | 2007-03-15 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウム及びその調製の方法 |
| WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
| CA2582449A1 (en) * | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Amorphous atorvastatin calcium |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| US20070032665A1 (en) * | 2005-08-04 | 2007-02-08 | Srinivasulu Gudipati | Preparation of atorvastatin calcium form i |
| CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| EP2132171A4 (en) * | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | NEW CRYSTALLINE FORMS OF PYRROLYLHEPTANIC ACID DERIVATIVES |
| US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| EP3578546A1 (en) | 2013-11-15 | 2019-12-11 | Akebia Therapeutics Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| EP3272336A1 (de) * | 2016-07-19 | 2018-01-24 | Stada Arzneimittel Ag | Atorvastatin-zusammensetzung |
| KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| JP3254219B2 (ja) * | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のｃｉ−９８１製剤およびその製法 |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| KR100431038B1 (ko) * | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| IN191236B (pl) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| CZ20021642A3 (cs) | 1999-11-17 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy atorvastatinu vápenatého |
| SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| EP1237865B1 (en) * | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| CZ20031495A3 (cs) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Forma VII hemi-kalcium atorvastatinu |
| HUP0303555A3 (en) * | 2000-11-16 | 2005-08-29 | Teva Pharma | Hydrolysis of [r(r |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| IN190564B (pl) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| RU2304139C2 (ru) | 2001-07-30 | 2007-08-10 | Д-р Редди'с Лабораторис Лтд | Кристаллические формы vi и vii кальциевой соли аторвастатина |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| HUP0500616A3 (en) | 2001-08-16 | 2011-07-28 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| WO2003018547A2 (en) | 2001-08-31 | 2003-03-06 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| MXPA04007939A (es) | 2002-02-15 | 2004-11-26 | Teva Pharma | Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix. |
| MXPA04007995A (es) | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. |
| US20060122403A1 (en) | 2002-09-03 | 2006-06-08 | Sanjay Suri | Atorvastatin calcium form vi or hydrates thereof |
| SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| EP1572643A2 (en) | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 US US10/370,897 patent/US7501450B2/en not_active Expired - Fee Related
- 2003-11-12 CA CA 2505968 patent/CA2505968C/en not_active Expired - Fee Related
- 2003-11-12 EP EP03786723A patent/EP1465865A2/en not_active Withdrawn
- 2003-11-12 AU AU2003295529A patent/AU2003295529A1/en not_active Abandoned
- 2003-11-12 WO PCT/US2003/036428 patent/WO2004043918A2/en not_active Ceased
- 2003-11-12 PL PL377555A patent/PL377555A1/pl not_active Application Discontinuation
-
2004
- 2004-04-30 LV LVP-04-52A patent/LV13214B/en unknown
-
2008
- 2008-09-30 US US12/286,594 patent/US20090143459A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043918A3 (en) | 2004-07-15 |
| AU2003295529A1 (en) | 2004-06-03 |
| WO2004043918A2 (en) | 2004-05-27 |
| US20090143459A1 (en) | 2009-06-04 |
| CA2505968A1 (en) | 2004-05-27 |
| EP1465865A2 (en) | 2004-10-13 |
| LV13214B (en) | 2005-02-20 |
| CA2505968C (en) | 2008-08-05 |
| US20030212279A1 (en) | 2003-11-13 |
| US7501450B2 (en) | 2009-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0600538A3 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| AU2003295529A1 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| EP1480950A4 (en) | NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX | |
| TWI350291B (en) | Crystal of anti-egfr antibodies | |
| PL1564202T3 (pl) | Nowy sposób syntezy i nowa postać krystaliczna agomelatyny, jak też zawierające ją kompozycje farmaceutyczne | |
| AU2003245572A1 (en) | Preparation of chiral amino-nitriles | |
| IL159626A0 (en) | Crystalline forms of atorvastatin calcium and processes for the preparation thereof | |
| AU2002368505A1 (en) | Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates | |
| IL175515A0 (en) | Process for preparation of statins with high synto antiratio | |
| IL180708A0 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation | |
| AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| ZA200508204B (en) | Pharmaceutical composition of atorvastatin | |
| IL187886A0 (en) | Crystal form of atorvastatin hemi -calcium and processes for preparation thereof | |
| ZA200405548B (en) | Process for the preparation of high purity perindopril and intermediates useful in the synthesis | |
| AU2002325845A1 (en) | Preparation process for atorvastatin and intermediates | |
| AU2003217438A1 (en) | Novel crystalline forms of levetiracetam | |
| IL173012A0 (en) | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin | |
| AU2002356423A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| AU2003302645A1 (en) | Synthesis of pyrrolidine compound and salt thereof | |
| HK1060294A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| AU2002322445A1 (en) | Crystals and structures of arnb aminotransferases | |
| EP1486485A4 (en) | NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS | |
| PL1622926T3 (pl) | Nowy sposób i produkty pośrednie wytwarzania związków 19-norsteroidów fluorowcowanych w pozycji 17 | |
| AU2003267944A1 (en) | Novel trifluoromethylepinephrine compounds and methods of making and using thereof | |
| AU2003235129A1 (en) | Process for preparation of 2-aminoketones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |